NCT00298181 - YSPSL for Prevention of Delayed Graft Function Part A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

December 31, 2007

Conditions

Delayed Graft Function

Interventions

DRUG

YSPSL

YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg

Trial Locations (10)

Westchester Medical Center, New York Medical College, Hawthorne

Lifelink Foundation, Tampa

Methodist Healthcare University Hospital, Memphis

University of Cincinnati, Department of Internal Medicine, Cincinnati

Rush University Medical Center, Chicago

Baylor University Medical Center Transplantation Services, Dallas

University of Texas, Organ Transplantation, Houston

Dumont-UCLA Transplant Center, Los Angeles

California Pacific Medical Center Department of Transplantation, San Francisco

Saint Barnabas Medical Center, Livingston

All Listed Sponsors

lead

Y's Therapeutics, Inc.

INDUSTRY